ArticleCureus2025
Bone Mineral Density Assessment by Dual-Energy X-Ray Absorptiometry (DEXA) Versus Serum Tartrate-Resistant Acid Phosphatase 5b (TRAP-5b) in Children With Classic Salt-Losing Congenital Adrenal Hyperplasia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic glucocorticoid (cGC) therapy is a leading cause of drug-induced osteoporosis, often resulting in severe bone loss. Bone mineral density (BMD) is maintained by a dynamic balance between bone formation and resorption, regulated by various hormones, vitamin D, and cytokines. BMD is typically measured using dual-energy X-ray absorptiometry (DEXA). Tartrate-resistant acid phosphatase 5b (TRAP-5b) serves as a biomarker of bone resorption and is utilized to assess osteoclast activity.
objectivesThis study aimed to evaluate BMD by measuring serum TRAP-5b levels in patients with congenital adrenal hyperplasia (CAH) receiving steroid therapy.
methodsForty patients with CAH underwent DEXA scans to assess BMD. Patients were then divided into two groups: one with normal BMD (n=14) and the other with abnormal BMD (n=26). Serum TRAP-5b levels were measured as a marker of bone turnover.
resultsChildren with CAH had significantly lower BMD in both the vertebrae and femoral neck. TRAP-5b levels were significantly higher in the abnormal BMD group (2.95 U/L) compared to the normal BMD group (p<0.001), indicating increased bone resorption in CAH.
conclusionsSerum TRAP-5b activity may be a significant diagnostic and prognostic marker for bone disease in CAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.